Brainstorm Cell Therapeutics Inc (BCLI)

Shares of Brainstorm Cell Therapeutics Inc. (BCLI) were down 47.73% to $0.20 after the company announced the FDA Advisory Committee voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.

https://www.benzinga.com/news/earnings/23/09/34981141/crude-oil-moves-lower-carmax-posts-downbeat-earnings

Brainstorm Cell Therapeutics Inc. (BCLI) fell 47.57% to $0.4277 after the FDA said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company's ALS therapy is reasonably likely to predict clinical benefit.

https://www.benzinga.com/news/23/09/34873722/why-brainstorm-cell-therapeutics-shares-are-trading-lower-by-33-here-are-other-stocks-moving-in-mond